<DOC>
	<DOCNO>NCT00002738</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , trimetrexate glucuronate leucovorin , use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : This phase II trial study well combination chemotherapy work treat child recurrent acute lymphoblastic leukemia , recurrent osteosarcoma , refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Acute Lymphoblastic Leukemia , Osteosarcoma , Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy trimetrexate glucuronate leucovorin calcium rescue child recurrent acute lymphoblastic leukemia , recurrent osteogenic sarcoma , refractory non-Hodgkin 's lymphoma resistant methotrexate . - Evaluate toxicity treatment regimen patient population . OUTLINE : Patients stratify accord disease ( acute lymphocytic leukemia , non-Hodgkin 's lymphoma v osteogenic sarcoma ) . Patients receive trimetrexate glucuronate orally IV every 12 hour day 1-21 oral leucovorin calcium every 12 hour day 1-24 . Treatment repeat every 4 week . Patients stable responsive disease may receive 4 course therapy . PROJECTED ACCRUAL : A total 25 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Trimetrexate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic evidence one follow malignancy fail conventional therapy : Acute lymphoblastic leukemia NonHodgkin 's lymphoma bone marrow involvement Osteogenic sarcoma In vitro transport resistance methotrexate demonstrate bone marrow aspirate assay PATIENT CHARACTERISTICS : Age : 21 diagnosis Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Granulocytopenia allow bone marrow involvement Thrombocytopenia allow bone marrow involvement Anemia allow bone marrow involvement Hepatic : ( unless due disease ) Bilirubin great 2.0 mg/dL AST great 100 Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No serious medical illness Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior bone marrow transplantation allow Chemotherapy : At least 1 week since prior intrathecal treatment At least 2 week since prior systemic chemotherapy recover At least 10 day rapidly proliferate leukemia ( i.e. , WBC great 50,000 ) No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow recover No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
</DOC>